Read by QxMD icon Read


İrem Koç, Sibel Kadayıfçılar, Bora Eldem
OBJECTIVE: To compare the visual and anatomical outcomes of intravitreal ranibizumab (group 1), bevacizumab (group 2), and triamcinolone (group 3) for center-involving diabetic macular edema. METHODS: We retrospectively enrolled 275 eyes of 208 consecutive patients. Visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and central macular thickness (CMT) values on optical coherence tomography were extracted. Reported side effects were noted...
October 20, 2017: Ophthalmologica. Journal International D'ophtalmologie
Atsushi Sugiyama, Yoichi Sakurada, Shigeru Honda, Akiko Miki, Wataru Matsumiya, Seigo Yoneyama, Wataru Kikushima, Hiroyuki Iijima
PURPOSE: The aim of this study was to investigate the clinical implications of required retreatment after 3-monthly intravitreal ranibizumab (IVR) injections followed by as-needed reinjections up to 5 years in eyes with exudative age-related macular degeneration (AMD). METHODS: A retrospective cohort study was conducted for 165 treatment-naïve eyes from 165 patients with exudative AMD. Visual changes were investigated in terms of the required retreatments. RESULTS: Retreatment-free proportions were 37...
October 19, 2017: Ophthalmologica. Journal International D'ophtalmologie
(no author information available yet)
TOPIC: A comparison between ranibizumab and bevacizumab of the incidence of systemic serious adverse events (SAEs) among patients with neovascular age-related macular degeneration (nAMD) who participated in a large-scale randomized trial. Use of individual patient data, rather than aggregate data, allowed adjustment for strong predictors of SAEs. CLINICAL RELEVANCE: Relative safety of ranibizumab and bevacizumab is important in choosing an anti-VEGF drug for the hundreds of thousands of patients with nAMD treated each year worldwide...
September 2017: Ophthalmology retina
Mehmet Tetikoğlu, Zafer Yüksel, Serdar Aktas, Haci Murat Sağdik, Fatih Özcura
PURPOSE: To investigate the association between VEGF gene polymorphisms and the responses to treatment with intravitreal ranibizumab (IVR) in patients with diabetic macular edema (DME). METHODS: This prospective study, conducted at the Kutahya Dumlupinar University Faculty of Medicine, included 95 patients with DME that were treated with IVR and 32 patients without DME despite proliferative diabetic retinopathy (PDR). The participants were divided into three groups: DME with non-proliferative diabetic retinopathy, DME with PDR, and PDR without DME; patients with DME who were treated with IVR were further divided into two groups based on their response to the treatment...
October 13, 2017: International Ophthalmology
Colin S Tan, SriniVas R Sadda
Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents...
2017: Clinical Ophthalmology
William Rhoades, Drew Dickson, Quan Dong Nguyen, Diana V Do
Central retinal vein occlusion (CRVO) can cause vision loss. The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab and they are effective at blocking VEGF...
April 2017: Taiwan Journal of Ophthalmology
Malini Bakthavatchalam, Frank H P Lai, Shi Song Rong, Danny S Ng, Marten E Brelen
There are various treatments for cystoid macular edema (CME) secondary to retinitis pigmentosa (RP); however, the evidence for these treatments has not been previously systematically reviewed. Our review that includes 23 studies shows that oral carbonic anhydrase inhibitors (CAI) (including acetazolamide, methazolamide) and topical CAI (dorzolamide and brinzolamide) are effective first line treatments. In patients unresponsive to CAI treatment, intravitreal steroids (triamcinolone acetonide and sustained-release dexamethasone implant), oral corticosteroid (Deflazacort), intravitreal anti-vascular endothelial growth factor agents (ranibizumab and bevacizumab), grid laser photocoagulation, pars plana vitrectomy, or ketorolac were also effective in improving CME secondary to RP...
October 4, 2017: Survey of Ophthalmology
Anna L Ells, Jason D Wesolosky, April D Ingram, Patrick C Mitchell, Alexander S Platt
OBJECTIVE: The aim of this study was to evaluate the visual and structural outcomes of eyes that received ranibizumab as treatment for retinopathy of prematurity (ROP). METHODS: This was a retrospective case series of infants who received a 0.2 mg (0.02 mL) intravitreal injection of ranibizumab as the primary treatment for type 1 ROP. Outcome measures included regression or recurrence of ROP, complications of treatment, and assessment of visual acuity and refractive error...
October 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
Han Joo Cho, Hyun Ji Hwang, Hyoung Seok Kim, Jung Il Han, Dong Won Lee, Jong Woo Kim
PURPOSE: To compare the effectiveness of intravitreal injection of aflibercept with ranibizumab in patients with Type 3 neovascularization. METHODS: Sixty-three treatment-naive eyes with Type 3 neovascularization (58 patients) were retrospectively analyzed. The eyes had received intravitreal aflibercept or ranibizumab injections. All patients were treated using an initial series of three monthly loading injections, followed by further injections as required. The visual and anatomical outcomes of treatment were evaluated after 12 months...
October 3, 2017: Retina
Adrian Koh, Timothy Y Y Lai, Kanji Takahashi, Tien Y Wong, Lee-Jen Chen, Paisan Ruamviboonsuk, Colin S Tan, Chrystel Feller, Philippe Margaron, Tock H Lim, Won Ki Lee
Importance: Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-related macular degeneration among Asian individuals. To our knowledge, there are no large randomized clinical trials to evaluate intravitreal ranibizumab, with and without verteporfin photodynamic therapy (vPDT), for the treatment of PCV. Objective: To compare the efficacy and safety of combination therapy of ranibizumab and vPDT with ranibizumab monotherapy in PCV. Design, Setting, and Participants: A double-masked, multicenter randomized clinical trial of 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading Center using indocyanine green angiography was conducted between August 7, 2013, and March 2, 2017...
October 5, 2017: JAMA Ophthalmology
M V Budzinskaya, A A Plyukhova, P A Sorokin
With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections...
2017: Vestnik Oftalmologii
Leticia Ortega-Evangelio, Javier Navarrete-Sanchis, Basil K Williams, Juan Miguel Tomás-Torrent
PURPOSE: Acute retinal necrosis (ARN) is a panuveitis syndrome that may lead to severe complications such as cystoid macular edema (CME). There is no consensus about the best treatment. We report one case of CME secondary to ARN managed with intravitreal aflibercept. CASE REPORT: A 41-year-old woman with a history of successfully treated varicella-zoster virus-associated ARN developed an epiretinal membrane (ERM) and underwent pars plana vitrectomy, ERM removal, inner limiting membrane peel, and lensectomy...
September 14, 2017: European Journal of Ophthalmology
Nikolle W Tan, Kyoko Ohno-Matsui, Hyoung J Koh, Yoshimi Nagai, Montse Pedros, Rita L Freitas, Wayne Macfadden, Timothy Y Lai
PURPOSE: To evaluate long-term efficacy and safety of ranibizumab for treatment of myopic choroidal neovascularization (mCNV) in clinical practice. METHODS: Noninterventional, retrospective cohort study of East-Asian patients previously treated with ranibizumab during the RADIANCE trial. Forty-one patients who completed the RADIANCE trial were followed-up for up to 48 months (post-RADIANCE observation period). Outcome measures were best-corrected visual acuity changes from baseline (assessed at RADIANCE trial initiation), mCNV recurrences, and ocular adverse events...
September 27, 2017: Retina
Svetlana N Tultseva, Yury S Astakhov, Sergei A Novikov, Pavel A Nechiporenko, Alla B Lisochkina, Andranik Y Ovnanyan, Sergei Y Astakhov
Purpose: We compared the efficacy and safety of ranibizumab versus ranibizumab plus scatter laser photocoagulation (SLP) in patients with chronic post-central retinal vein occlusion (CRVO) macular edema (ME). Methods: This prospective non-randomized pilot study included 250 patients with peripheral retinal ischemia and CRVO-related ME. The mean follow-up period was 24.5 ± 6.5 months. The clinical assessments conducted included best corrected visual acuity, optical coherence tomography, and multi-field fluorescein angiography with measurement of the ischemic area...
July 2017: Arquivos Brasileiros de Oftalmologia
Justus G Garweg, Sophie A Niderprim, Hanna Maria Russ, Isabel B Pfister
PURPOSE: In several case-studies improved outcomes have been reported after switching from a pro-re-nata (PRN)- to a treat-and-extend (T&E)-based therapeutic approach in cases of neovascular age-related macular degeneration (nAMD). We therefore wished to compare the effects of instigating 2 different protocols in newly-diagnosed nAMD undergoing treatment with Ranibizumab. METHODS: The outcomes of a PRN- and a T&E-based regime were retrospectively compared in treatment-naïve eyes under therapy with Ranibizumab for minimally 12 months in a routine clinical setting...
September 27, 2017: Journal of Ocular Pharmacology and Therapeutics
Philip Enders, Vasilena Sitnilska, Lebriz Altay, Sascha Fauser
PURPOSE: To compare changes of retinal morphology in the first weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD). PROCEDURES: In a prospective study 50 patients with active choroidal neovascularization secondary to nAMD were monitored weekly by spectral-domain optical coherence tomography for 3 weeks after treatment. Twenty-two patients received bevacizumab, 15 ranibizumab, and 13 aflibercept. Morphological parameters of retinal compartments were compared...
September 27, 2017: Ophthalmologica. Journal International D'ophtalmologie
Shafi Balal, Jonathan Than, Sharmila Tekriwal, Aires Lobo
PURPOSE: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab. METHODS: We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up. RESULTS: Patients (n = 129) had a mean follow-up of 19...
September 27, 2017: Ophthalmologica. Journal International D'ophtalmologie
J Cui, D Sun, H Lu, R Dai, L Xing, H Dong, L Wang, D Wei, B Jiang, Y Jiao, M M Jablonski, S Charles, W Gu, H Chen
PurposeTo compare the efficacy and safety of conbercept and ranibizumab when administered according to a treat-and-extend (TREX) protocol for the treatment of neovascular age-related macular degeneration (AMD) in China.Patients and methodsBetween May 2014 and May 2015, 180 patients were treated in a 1 : 1 ratio using conbercept or ranibizumab from four hospitals. Patients received either conbercept 0.5 mg or ranibizumab 0.5 mg intravitreal injections. Follow-up time was 1 year and treated based on a TREX approach...
September 22, 2017: Eye
Lei Liu, Yih-Chung Tham, Jingyang Wu, Song Yue, Ching-Yu Cheng
PURPOSE: To perform a systematic review and meta-analysis to compare the outcome and serious adverse effects of intravitreal ranibizumab (IVR) monotherapy vs. combined treatment of IVR and photodynamic therapy (PDT) on polypoidal choroidal vasculopathy (PCV). METHODS: A computerized online search was performed using PubMed, EMBASE, Cochrane Library, Web of Science and China National Knowledge Infrastructure (CNKI) database. The quality of included studies was evaluated according to the Newcastle-Ottawa Scale...
September 18, 2017: Photodiagnosis and Photodynamic Therapy
Xiao'an Liu, Yangfan Yang, Xiujuan Guo, Liling Liu, Kaili Wu, Minbin Yu
Abstracts Purpose: Pirfenidone is mostly used in antifibrotic and anti-inflammatory therapies. We have previously demonstrated that pirfenidone had antifibrotic and anti-inflammatory effects on the wound healing process after glaucoma filtration surgery in vitro and in vivo. Since the wound healing and reactive scarring process simultaneously involves inflammation, fibrosis, and angiogenesis, and angiogenesis plays a more important role in chronic or prolonged wound healing, we tried to explore the antiangiogenesis effect in pirfenidone and its potential multitarget function in regulating excessive scarring...
November 2017: Journal of Ocular Pharmacology and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"